Impact BioMedical Inc. (IBO)

Impact BioMedical Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	-	-	0.05	-	-
Gross Profit	-	-	0.05	-	-
Selling, General & Admin	1.83	1.1	1.12	0.99	0.38
Research & Development	0.28	1.69	1.23	1.08	0.51
Other Operating Expenses	0.17	0.12	-	-	-
Operating Expenses	3.4	4.03	3.45	3.19	0.9
Operating Income	-3.4	-4.03	-3.4	-3.19	-0.9
Interest Expense	-1.07	-0.44	-0.46	-0.3	-
Interest & Investment Income	0.01	0.01	0.02	0.17	-
Other Non Operating Income (Expenses)	5.07	0.05	0.07	0.08	-
EBT Excluding Unusual Items	0.62	-4.41	-3.78	-3.24	-0.9
Impairment of Goodwill	-25.09	-	-	-	-
Gain (Loss) on Sale of Investments	-	-	-4.1	-	-
Asset Writedown	-0.26	-	-	-	-
Pretax Income	-24.74	-4.41	-7.88	-3.24	-0.9
Income Tax Expense	0.03	-	-0.62	-1.4	-0.08
Earnings From Continuing Operations	-24.77	-4.41	-7.26	-1.85	-0.81
Minority Interest in Earnings	0.06	0.07	0.2	0.55	0.22
Net Income	-24.71	-4.34	-7.05	-1.3	-0.6
Net Income to Common	-24.71	-4.34	-7.05	-1.3	-0.6
Shares Outstanding (Basic)	11	60	70	70	70
Shares Outstanding (Diluted)	11	60	70	70	70
Shares Change (YoY)	-82.14%	-14.54%	-	-	-
EPS (Basic)	-2.30	-0.07	-0.10	-0.02	-0.01
EPS (Diluted)	-2.30	-0.07	-0.10	-0.02	-0.01
Free Cash Flow	-3.92	-2.87	-2.52	-2.03	-0.9
Free Cash Flow Per Share	-0.36	-0.05	-0.04	-0.03	-0.01
Gross Margin	-	-	100.00%	-	-
Operating Margin	-	-	-6808.00%	-	-
Profit Margin	-	-	-14102.00%	-	-
Free Cash Flow Margin	-	-	-5036.00%	-	-
EBITDA	-3.39	-4.02	-2.29	-2.07	-
D&A For EBITDA	0.01	0.01	1.11	1.11	-
EBIT	-3.4	-4.03	-3.4	-3.19	-0.9

Updated Nov 12, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q